Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva's Cinqair OK'd, But Narrower Use Than GSK's Nucala

This article was originally published in Scrip

Executive Summary

Teva Pharmaceutical Industries Ltd. gained US approval on March 23 to market Cinqair (reslizumab) as an add-on maintenance treatment for adults 18 years or older with severe asthma with an eosinophilic phenotype.

You may also be interested in...



Teva Gets EU Green Light For Reslizumab

Teva is set to get its severe asthma treatment Cinqaero onto the EU market following a positive opinion from the CHMP but, as in the US, its label will restrict its use to adult patients.

AstraZeneca Hopes To Differentiate Benralizumab On Efficacy, Dosing Convenience

AstraZeneca PLC is keeping a tight lid on Phase III data for its biologic for severe asthma, benralizumab, other than to say it met its primary endpoint in a pair of pivotal trials – but the pharma hopes to offer differentiating efficacy from GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. biologics already approved for this indication when it unveils the full datasets at a scientific meeting later this year.

Moderna's Valera Takes mRNA Approach To Combat Zika

With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.

Topics

UsernamePublicRestriction

Register

PL032870

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel